Kadmon Holdings Inc

Kadmon — Investor Presentation (March 2017)

34 slides from Kadmon's investor presentation, Mar 8, 2017

  1. Slide 1: Kadmon Corporate Presentation

    8 Kadmon Corporate Presentation

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement This presentation contains “forward-looking” statements that are based on the beliefs and assumptions and on information currently available to management of Kadmon Holdings, Inc. (the ‘Company’. All statements other than statements of historical fact contained in this pres

  3. Slide 3: Company Highlights

    Company Highlights Diverse, Science-driven Clinical Pipeline Leader in R&D of ROCK Inhibitors Biologics Platform D025: ROCK2 inhibitor — In Phase 2 for moderate to severe psoriasis — In Phase 2 for idiopathic pulmonary fibrosis — In Phase 2 for chronic graft-versus-host disease Tesevatinib: Brain-pe

  4. Slide 4: Innovative Pipeline for Major Significant Medical Needs

    Innovative Pipeline for Major Significant Medical Needs Preclin. | Phase 4 Clinical Stage Compounds | Indication Moderate to Severe Psoriasis > (RocK2 | |“opathic Pulmonary Fibrosis a, A (IPF) Chronic Graft-Versus-Host | Disease (CGVHD) NSCLC with Brain Metastases ue, or Leptomeningeal Disease Oncol

  5. Slide 5: ROCK Inhibitor Platform

    ROCK Inhibitor Platform Autoimmune, Fibrotic and Neurodegenerative Diseases

  6. Slide 6: Kadmon's Target: Rho-associated Protein Kinase (ROCK)

    Kadmon’s Target: Rho-associated Protein Kinase (ROCK) Kadmon is Develo; lors for Several Diseases ig Oral Selective ROCK In! e ROCK is a moleculartarget with substantial therapeutic potential across multiple disease areas: — Autoimmune diseases — Fibrotic diseases — Neurodegenerative diseases ¢ TwoR

  7. Slide 7: Kadmon's Lead ROCK Inhibitor: KD025

    Kadmon’s Lead ROCK Inhibitor: KDO25 KD025, an Oral Selective ROCK2 Inhibitor in Phase 2 Developmer e Eight completed Phase 1 and Phase 2 clinical studies of KD025 in more than 180 subjects, in doses rangingfrom 20 mg to 1,000 mg; KD025 was well tolerated across all studies — Phase 1 safety data in h

  8. Slide 8: Kadmon has Defined a Key Role of ROCK2 in Autoimmune Disease

    Kadmon has Defined a Key Role of ROCK2 in Autoimmune Disease ROCK2 inhibition with KD025 down-regulates the pro-inflammatory response while potentially avoiding limitations of current biologic therapies, including increased risk of serious infections and malignancies Autoimmune Disease * Autoimmunit

  9. Slide 9: KD025 Inhibits Th17 Cytokine Secretion in Healthy Human Cells

    KD025 Inhibits Th17 Cytokine Secretion in Healthy Human Cells (in vitro analysis) KD025 Down-Regulates Secretion of Th17 Inflammatory Cytokines Ir 124 22 5 08 as 4 - 04 ve: as 03 z Eos £ 22 3 302 1 a2 o4 ° ° ° o 42° 25 5 Ot o 42 28 5 | 0 o 42 28 5 | > > > 0025 (ul) 0025 (ul) 0025 (uM) No Deleterious

  10. Slide 10: KD025 in Psoriasis: PASI Score Improvement in 85% of Patients

    KD025 in Psoriasis: PASI Score Improvement in 85% of Patients Patients Completing Phase 2 Study of KD025in Psoriasis Who Achieved PASI 50 42% 71% (6/12 patients) (6/7 patients) i Month 2, Day 4 Hi onth 2, bay 1 I Ena of Treatment % of Patients Achieving PASI50 400 mg QD 200 mg BID Completed Phase 2,

  11. Slide 11: KD025: Ongoing Phase 2 Study in Psoriasis

    KD025: Ongoing Phase 2 Study in Psoriasis Market Size: Moderate to Severe Psoriasis e Psoriasis affectsas many as 7.5 million people in the United States e Need fornovel oral agents that lack gastrointestinal side effects Continued Development of KD025 in Moderateto Severe Psoriasis e Ongoing, rando

  12. Slide 12: ROCK Plays Key Role in Fibrotic Disease

    ROCK Plays Key Role in Fibrotic Disease e Fibrosisis a consequence of aberrant wound-healing — Prolonged activation of myofibroblasts can result in permanent scarring, organ malfunction and death e ROCK is key common pathway and therapeutic target for pathologic fibrosis — ROCK inhibition reduces co

  13. Slide 13: ROCK Mediates Multiple Pro-Fibrotic Processes

    ROCK Mediates Multiple Pro-Fibrotic Processes Lung Fibrosis Progression KD025 targets these specific processes Cell Type Pathophysiology + TGF activation + Expression of CTGF + Paracellular gap [| « Fibroblast + Contractile gene formation differentiation to [| expression myofibroblast [J + Collagen

  14. Slide 14: KD025 Attenuates Pulmonary Fibrosis in Bleomycin-Induced Mouse Model

    KD025 Attenuates Pulmonary Fibrosis in Bleomycin-Induced Mouse Model Intratracheal Bleomycin KD025 treatment administered when + fibrosis is already established | comeeniimmmen (orally, 50, 100 or 150 mg QD) 1 Vehicle or KDO25 Day 8 Intratracheal Bleomycin Day 0

  15. Slide 15: KD025 in Fibrotic Disease: Ongoing Clinical Study

    KD025 in Fibrotic Disease: Ongoing Clinical Study Market Size: Idiopathic Pulmonary Fibrosis 128,000 people in the United States are living with IPF, with 48,000 newcases diagnosed annually Median survival after IPF diagnosis is approximately 2-3 years KD025: Ongoing Study in Idiopathic Pulmonary Fi

  16. Slide 16: KD025: Ongoing Phase 2 Study in cGVHD

    KD025: Ongoing Phase 2 Study in cGVHD cGVHD Background e cGVHDis a commonand often fatal complication following allogeneic stem cell transplantation — Transplanted immune cells attack recipienttissue, leading to fibrosis in the lung, Gl tract, liver and skin — ROCK signaling pathway regulates IL-21

  17. Slide 17: Tesevatinib

    Tesevatinib Oncology and Polycystic Kidney Disease

  18. Slide 18: Tesevatinib: A Unique Tyrosine Kinase Inhibitor for Oncology

    Tesevatinib: A Unique Tyrosine Kinase Inhibitor for Oncology Tesevatinib: Distinguishing Characteristics e Oral, reversible and highly potent EGFR inhibitor — Alsoinhibits VEGFR2, HER2 and Src family kinases e Highly blood-brain barrier penetrant: 1:1 brain/blood ratio — Compared to <0.15:1 brain/bl

  19. Slide 19: NSCLC Study: Encouraging Results in First Patients

    NSCLC Study: Encouraging Results in 11 of First 13 Patients Ongoing Phase 2 Study in NSCLC with Brain Metastases or Leptomeningeal Disease « NSCLC patients with activating EGFR mutations receiving tesevatinib 300 mg QD: — Brain metastases (BM) (third-line treatment) — Leptomeningeal metastases (LM)

  20. Slide 20: NSCLC Study: Patient With BM and LM Sees Improvement

    NSCLC Study: Patient With BM and LM (034-002) Sees Improved Right Parieto-Occipital Leptomeningeal Enhancement 20

  21. Slide 21: NSCLC Study: Patient With BM Sees ~50% Overall Decrease

    NSCLC Study: Patient With BM (045-003) Sees ~50% Overall Decrease in Brain Metastases 21

  22. Slide 22: Tesevatinib: Clinical Plan in NSCLC with CNS Metastases

    Tesevatinib: Clinical Plan in NSCLC with CNS Metastases Market Size: EGFR-Mutant NSCLC with CNS Metastases e NSCLC with activating EGFR mutations with brain metastases or leptomeningeal metastases —- EGFR activating mutations occur in ~20% of NSCLC patients in the United States — ~50% of tumors driv

  23. Slide 23: Tesevatinib: Exploratory Study in Glioblastoma

    Tesevatinib: Exploratory Study in Glioblastoma Tesevatinib in Glioblastoma Ongoing exploratory Phase 2 study of tesevatinib in recurrent glioblastoma — Glioblastomais a primary brain tumor and represents a major unmet medical need — EGFR gene abnormalities are commonin glioblastomas: + >50% of gliom

  24. Slide 24: Tesevatinib: Polycystic Kidney Disease Pathophysiology

    Tesevatinib: Polycystic Kidney Disease Pathophysiology Tesevi uniquely po: e Most prevalent monogenic disease with no approved therapies inthe U.S. — 600,000 PKD patients in U.S.; 12.5 million worldwide — Autosomal dominant PKD (ADPKD) presents in adulthood — Autosomal recessive PKD (ARPKD) presents

  25. Slide 25: Tesevatinib: Effective in PKD Rat and Mouse Models

    Tesevatinib: Effective in PKD Rat and Mouse Models Vehice Tesevatnb —Tesevatin Nome Gpeased—Tesevsin) Tesevatnt ‘7.Smgikg/day —1Emg/ka/day 7.Smgikgiday —1Smghkalday ‘15mg/kg/day

  26. Slide 26: Tesevatinib in ADPKD: Ongoing Study and Clinical Plan

    Tesevatinib in ADPKD: Ongoing Study and Clinical Plan Ongoing, Open-Label, Dose-Finding Phase 2a Study: Safety and Tolerability at 50 mg QD Study initiated in 2012; 61 patients enrolled « No drug-related SAEs ¢ No significant increase in kidney size; no change in kidney function e New data supportte

  27. Slide 27: Tesevatinib in ARPKD: Clinical Plan

    Tesevatinib in ARPKD: Clinical Plan ARPKOD: Planned Phase1 Study ¢ Tesevatinib reformulated for liquid dosing e Developmental toxicology completed Planned Phase 1, ascending single-dose safety study of tesevatinib in ARPKD patients ages 5 to 12 « Two clinical sites selected Three cohorts planned (te

  28. Slide 28: KD034 Portfolio

    KD034 Portfolio Wilson’s Disease

  29. Slide 29: KD034: Enhanced Formulations of Trientine for Wilson's Disease

    KD034: Enhanced Formulations of Trientine for Wilson’s Disease Kadmon is Developing Convenient Forms of Wilson’s Disease Therapies e Wilson’s Disease: Orphan genetic liver disease, major unmet medical need — 10,000 living with Wilson’s Disease in the United States — Requires lifelong treatment — Cur

  30. Slide 30: Preclinical Programs

    Preclinical Programs

  31. Slide 31: Kadmon: Preclinical Pipeline

    Kadmon: Preclinical Pipeline Near-Term Immuno-Oncology Collaboration Opportunity * Lead candidate: KD035, an anti-VEGFR2 antibody being developed for anti-angiogenesis indications * Also developing KD033, a unique anti-PD-L1/IL-15 fusion protein * Completed biologics licensing agreement with Jinghua

  32. Slide 32: Multiple Data Readouts Expected Throughout 2017 and 2018

    Multiple Data Readouts Expected Throughout 2017 and 2018 [Product ——_|indication 2017 2018 Tesevatnib = iaaaaaaaaal | | s (Oncology) . a qesevatnib: Autosomal Dominant (AD) PKD* O Ld is) ‘Autosomal Recessive (AR) PKD* | a | Moderate to Severe Psoriasis gq ROCK2 Inhibitor , rem cat yop lopathic Pulmo

  33. Slide 33: Company Highlights

    Company Highlights KD025: ROCK2 inhibitor — In Phase 2 for moderate to severe psoriasis — In Phase 2 for idiopathic pulmonary fibrosis — In Phase 2 for chronic graft-versus-host disease Tesevatinib: Brain-penetrant EGFR inhibitor that accumulates in leptomeninges and kidneys — In Phase 2 for NSCLC w

  34. Slide 34: Financial Profile

    Financial Profile KDMN Fi Summary e Kadmon completed its IPO on August 1, 2016; gross proceeds of $75mm e 45,078,666 common shares outstandingas of November8, 2016 e Trades onthe NYSE under the ticker symbol “KDMN” e Revenue of $21.8mm for the nine months ended September 30, 2016 KDMN LISTED NYSE

Kadmon Holdings — Investor Presentation (March 2017) on 6ix